Medical Weight Loss (GLP-1) in Aurora

Medical Weight Loss (GLP-1) generally runs CAD$340–CAD$2,040 per month, and each Aurora clinic sets its own price. The biggest variables are the provider's experience level and the specific device or product used. Newer technology and senior injectors price at the upper end. Pricing is quoted in Canadian dollars (CAD). Request a consultation from any of our listed Aurora clinics for a personalized quote.

ClinicCompass lists 2 verified Aurora-area clinics offering Medical Weight Loss (GLP-1), concentrated in Aurora. Each listing includes real Google ratings so you can compare reputable options side by side before booking a consultation.

Among our 2 listed Aurora providers for Medical Weight Loss (GLP-1), Velmont Medical Clinic has the strongest Google record once review volume is weighed: 4.9★ across 118 reviews (located in Aurora). "Best" is subjective. Compare 2–3 Aurora clinics before committing.

Significant weight loss often leaves two concerns GLP-1s alone don't fix: loose skin where fat was lost, and stubborn pockets that don't shrink with overall weight loss (love handles, lower belly, inner thighs). Many Aurora patients pair GLP-1 use with CoolSculpting or Emsculpt NEO during the maintenance phase to address stubborn fat, and with Morpheus8 or skin tightening for loose skin. Timing matters: most providers recommend reaching stable weight before doing body contouring.

Common: nausea (especially during dose increases, often resolves over 4–8 weeks), fatigue, constipation or diarrhea, decreased appetite, acid reflux. Less common but serious: pancreatitis, gallbladder issues, kidney problems with dehydration. The drugs carry a boxed warning for thyroid C-cell tumors. Patients with personal or family history of medullary thyroid cancer or MEN-2 syndrome should not take them. "Ozempic face" (facial volume loss from rapid weight loss) is common enough that many patients pair GLP-1 use with filler or Sculptra.

Clinical trial averages: semaglutide (Wegovy) patients lost approximately 15% of body weight over 68 weeks; tirzepatide (Zepbound) patients lost approximately 20–22% over 72 weeks. Real-world results vary widely: some patients lose more, some lose less, and a subset (5–15%) are "non-responders" who see minimal results. Most weight loss happens in the first 6–12 months as the dose is gradually escalated to the maximum tolerated level. Results require continued use; stopping typically leads to gradual weight regain.

Brand-name versions (Ozempic, Wegovy, Mounjaro, Zepbound) are FDA-approved, manufactured under strict regulatory oversight, and typically cost $1,000–$1,500/month without insurance. Compounded versions are made by compounding pharmacies. They're significantly cheaper ($200–$500/month) and were widely available during recent FDA-declared shortages. Important: as of 2025, FDA declared the semaglutide shortage resolved, and compounding under those rules is being phased out. Tirzepatide compounding is also under regulatory scrutiny. The FDA has issued warnings about quality control with some compounded versions. Ask any med spa exactly which formulation they use, where it's sourced, and whether it's currently compliant with FDA rules.

Compounded GLP-1 programs at med spas typically run $250–$500/month, including the medication, supplies, and monthly check-ins. Brand-name semaglutide (Wegovy) or tirzepatide (Zepbound) without insurance runs $1,000–$1,500/month. Most patients only afford the brand versions when insurance covers them. Med spa programs often bundle in initial labs ($150–$300 one-time), nutrition guidance, and dose adjustments. Telehealth-only services (Hims, Ro, Henry Meds) often price lower than med spas but provide less in-person support.

Common (most patients): nausea, especially during dose increases, often improves over 4–8 weeks. Other frequent side effects: fatigue, constipation, diarrhea, decreased appetite (which is partly the point), and acid reflux. Less common but more serious: pancreatitis, gallbladder issues (gallstones), kidney problems with severe dehydration. The drugs carry a boxed warning for thyroid C-cell tumors based on animal studies. Humans with personal or family history of medullary thyroid cancer or MEN-2 syndrome should not take these. "Ozempic face" refers to facial volume loss from rapid weight loss, common enough that many patients pair GLP-1 use with fillers or Sculptra to maintain facial volume.

Most patients regain a meaningful portion of lost weight within 12 months of stopping: roughly two-thirds of people who stop semaglutide, and about half who stop tirzepatide, regain the weight unless their eating patterns and exercise have changed significantly. This is because GLP-1s primarily work by suppressing appetite while you're on them; the underlying biology of weight regulation doesn't permanently change. To maintain results long-term, patients either continue indefinitely (at a maintenance dose, typically lower than the weight-loss dose) or pair the medication with sustained lifestyle changes during treatment. "How do I get off GLP-1" is one of the most-discussed topics in patient communities. Discuss exit strategy with your provider before starting.

Each has trade-offs. **Med spa**: In-person care, often offers compounded versions at lower cost than brand-name, may include nutrition counseling and body contouring add-ons (CoolSculpting, Emsculpt), monthly supervision. **Primary care doctor**: Best for navigating insurance coverage of brand-name versions, integrating with existing health management, longer-term medical relationship. **Telehealth (Hims/Henry/Ro)**: Lowest cost, fast approval, fully online, but less personalized care and limited support for complications. Most patients who want compounded options and in-person guidance choose med spas; those with insurance coverage often go through their primary care doctor.

FDA-approved indications: BMI 30+ (obese), or BMI 27+ (overweight) with a weight-related health condition like type 2 diabetes, prediabetes, high blood pressure, high cholesterol, or sleep apnea. Many med spas will treat patients with somewhat lower BMI on an off-label basis. Disqualifications: personal or family history of medullary thyroid cancer or MEN-2 syndrome, history of pancreatitis, severe gastrointestinal disease, pregnancy/breastfeeding, or active eating disorders. A proper med spa program should include initial labs, medical history review, and ongoing provider oversight, not just a quick form and an injection.

Significant weight loss often leaves two cosmetic concerns GLP-1s alone don't address: (1) loose skin where fat was lost, and (2) stubborn pockets of fat that don't respond to overall weight loss (love handles, lower abdomen, inner thighs). Many patients pair GLP-1 use with **CoolSculpting** or **Emsculpt NEO** in the maintenance phase (after most weight loss is complete) to address stubborn fat, and with **Morpheus8** or **skin tightening** to address loose skin. Combining is logical, but timing matters: most providers recommend reaching stable weight before doing body contouring.